Cabaletta Bio Pockets $128 Million From Expiring Warrants — But Can Cash Alone Cure a Stock Trading Below Its Exercise Price?

Shares of Cabaletta Bio rose 7.3% to $2.93 after the autoimmune-focused biotech disclosed it collected approximately $128.2 million in gross proceeds from common-stock warrants that expired September 12. The cash infusion removes a major financing overhang — but the stock still trades below levels that made these warrants attractive, raising hard questions about how much runway really buys.

$128 Million Fills the Tank, but the Burn Rate Is Fierce. Of the 53,090,190 warrants originally issued in a June 2025 offering at a $2.50 exercise price, about 5.3 million were exercised through June 30 for $13.2 million, while another 46 million were exercised between July 1 and expiration for roughly $115 million. That's critical because Cabaletta reported a net loss of $51 million in Q2 2026 alone, with operating expenses of $52 million for the quarter. At that pace, $128 million buys roughly two and a half additional quarters of operations — meaningful, but not transformative.

The Cash Pile Is Now Substantial — If You Ignore Dilution. Cabaletta held $225.1 million in cash and short-term investments as of June 30, before most of the warrant proceeds arrived. Adding $115 million exercised after that date pushes the pro-forma figure well above $300 million. Management previously said its mid-year cash position would fund operations into mid-2027. The warrant haul likely extends that runway further. But this comes at a cost: as of June 30, Cabaletta had 167.7 million shares outstanding, and the roughly 51.3 million new shares from exercised warrants push the total past 219 million — massively diluting existing holders.

The Real Bet Is the Drug, Not the Balance Sheet. Cabaletta's lead therapy — a cell treatment designed to reset the immune system in autoimmune diseases — targets a mid-2027 data readout in a muscle-inflammation condition that could support a formal application for FDA approval in late 2027.

Backers including Bain Capital, Eli Lilly, and Adage Capital participated in a $150 million stock offering in May, signaling institutional conviction. Still, with the stock at $2.93 — inside its $1.45–$4.22 52-week range — the market is pricing in substantial execution risk.

The Bottom Line: The warrant cash eliminated a near-term survival scare, but shareholders absorbed enormous dilution to get it. Everything now hinges on clinical data next year.